Cornerstone Wealth Management LLC boosted its stake in shares of Bruker Co. (NASDAQ:BRKR) by 15.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,379 shares of the medical research company’s stock after buying an additional 3,745 shares during the quarter. Cornerstone Wealth Management LLC’s holdings in Bruker were worth $903,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Chicago Equity Partners LLC grew its position in Bruker by 15.2% during the second quarter. Chicago Equity Partners LLC now owns 17,815 shares of the medical research company’s stock worth $517,000 after buying an additional 2,350 shares during the period. Dimensional Fund Advisors LP grew its position in Bruker by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 961,131 shares of the medical research company’s stock worth $27,912,000 after buying an additional 2,606 shares during the period. Ramsey Quantitative Systems grew its position in Bruker by 25.6% during the third quarter. Ramsey Quantitative Systems now owns 12,906 shares of the medical research company’s stock worth $432,000 after buying an additional 2,633 shares during the period. State of Alaska Department of Revenue grew its position in Bruker by 35.6% during the second quarter. State of Alaska Department of Revenue now owns 11,510 shares of the medical research company’s stock worth $334,000 after buying an additional 3,020 shares during the period. Finally, Guggenheim Capital LLC grew its position in Bruker by 7.6% during the first quarter. Guggenheim Capital LLC now owns 44,676 shares of the medical research company’s stock worth $1,336,000 after buying an additional 3,144 shares during the period. Institutional investors own 64.83% of the company’s stock.
Several brokerages have weighed in on BRKR. UBS Group began coverage on shares of Bruker in a research report on Tuesday, October 9th. They set a “sell” rating and a $30.00 target price on the stock. They noted that the move was a valuation call. ValuEngine lowered shares of Bruker from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. Morgan Stanley lowered shares of Bruker from an “equal weight” rating to an “underweight” rating and upped their target price for the stock from $31.00 to $32.00 in a research report on Thursday, September 20th. BidaskClub lowered shares of Bruker from a “buy” rating to a “hold” rating in a research report on Wednesday, September 19th. Finally, Zacks Investment Research lowered shares of Bruker from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Bruker presently has an average rating of “Hold” and an average price target of $33.90.
BRKR stock opened at $32.32 on Friday. The company has a market capitalization of $4.86 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 1.98 and a beta of 1.34. Bruker Co. has a 12 month low of $28.13 and a 12 month high of $36.53. The company has a current ratio of 2.22, a quick ratio of 1.27 and a debt-to-equity ratio of 0.26.
Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.30 by $0.07. The business had revenue of $466.60 million for the quarter, compared to analyst estimates of $451.88 million. Bruker had a net margin of 4.99% and a return on equity of 27.03%. The company’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 earnings per share. Equities analysts anticipate that Bruker Co. will post 1.38 EPS for the current fiscal year.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.